Xencor, Inc. (NASDAQ:XNCR) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET
Company Participants
Charles Liles - Head, Corporate Communications and Investor Relations
Bassil Dahiyat - President and Chief Executive Officer
John Desjarlais - Chief Scientific Officer
John Kuch - Chief Financial Officer
Allen Yang - Chief Medical Officer
Conference Call Participants
Ted Tenthoff - Piper Sandler
Jonathan Chang - SVB Leerink
Peter Lawson - Barclays
Arlinda Lee - Canaccord
Kaveri Pohlman - BTIG
Xinyue Lu - RBC Capital Markets
Zhi Shu - Berenberg
Operator
Good afternoon, ladies and gentlemen and thank you for standing by and welcome to the Second Quarter 2021 Xencor Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company’s request. Now, I would like to turn the call over to your speaker for today, Charles Liles, Head of Corporate Communications and Investor Relations.
Charles Liles
Thank you and good afternoon. Earlier today, we issued a press release which outlines the topics we plan to discuss today. It’s available at www.xencor.com.
Today on our call, Bassil Dahiyat, President and Chief Executive Officer will review recent business news and pipeline updates; John Desjarlais, Chief Scientific Officer will discuss our cytokine and CD28 programs; and John Kuch, Chief Financial Officer will review financial results. And then we will open up the call for your questions. And Allen Yang, Chief Medical Officer, will join us then.
Before we begin, I would like to remind you that during the course of this conference call, Xencor management may make forward-looking statements, including statements regarding the company’s future financial and operating results, future market conditions, the plans and objectives of management, future operations, the company’s partnering efforts, capital requirements, future product offerings and research and development programs. These forward-looking statements are not historical facts, but rather are based on our current expectations and beliefs and
- Read more current XNCR analysis and news
- View all earnings call transcripts